Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
September 2019—Randox launched at the AACC annual meeting the Randox Stroke Biochip, a highly sensitive blood test that complements CT scanning technology to facilitate accurate classification of stroke patients. The test differentiates between ischemic and hemorrhagic stroke, directs the appropriate patient care pathway, and enables rapid thrombolytic therapy.
September 2019—Veravas launched three biotin interference products, VeraTest Biotin, VeraPrep Biotin, and VeraBind Biotin, for research use only.
September 2019—Caris Life Sciences has entered into a strategic collaboration with Debiopharm for the development of a companion diagnostic test using Caris’ whole transcriptome sequencing assay for mRNA analysis called MI Transcriptome. The assay, which was granted breakthrough device designation by the FDA in May, detects rare fibroblast growth factor receptor (FGFR1, FGFR2, and FGFR3) fusion events.
September 2019—Streck introduced three antibiotic resistance detection kits and its blood collection tube at the AACC Annual Scientific Meeting and Clinical Lab Expo, Aug. 6-–8, in Anaheim, Calif.
September 2019—Meridian Bioscience has acquired Quebec City-–based GenePOC, a provider of molecular diagnostic instruments and assays.
September 2019—Quest Diagnostics announced the availability of its test panel to guide therapy with HIV pre-exposure prophylaxis, or PrEP. PrEP is the use of antiretroviral drugs to help prevent HIV infection in high-risk individuals who are not infected.
September 2019—Thermo Fisher Scientific previewed its Sensititre Aris HiQ AST System at the 71st annual AACC meeting. The benchtop automated reading and incubation system for antimicrobial susceptibility testing uses broth microdilution to provide minimum inhibitory concentration results.
September 2019—Ortho Clinical Diagnostics announced that its Vitros Immunodiagnostic Products HIV Combo Reagent Pack and Calibrator (Vitros HIV Combo test) has been granted FDA premarket approval for use on Ortho’s Vitros XT 7600 Integrated System. The Vitros HIV Combo is a fourth-generation test that detects HIV-1 and HIV-2 antibodies and the p24 antigen.
September 2019—MedTest Dx introduced at the 2019 American Association for Clinical Chemistry annual scientific meeting an improved line of Clinitox Calibrators and Controls for confirmation testing. The product line aims to provide laboratories performing drugs of abuse testing a comprehensive and reliable calibration and controls solution with extended shelf life and simplified documentation.
August 2019—The U.S. Food and Drug Administration authorized marketing of a diagnostic test to detect Zika virus immunoglobulin antibodies in human blood. The ZIKV Detect 2.0 IgM Capture ELISA (InBios, Seattle) is the first Zika diagnostic test the FDA has allowed to be marketed in the U.S.; previously, tests for detecting Zika virus IgM antibodies, including the InBios test, had been authorized only for emergency use.
